Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (10)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

2022

  1. 48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort

    PLoS ONE, Vol. 17, Núm. 11 November

  2. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

2020

  1. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure

    Antiviral Research, Vol. 174

  2. Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients

    Medicine (United States), Vol. 97, Núm. 38

  2. Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment

    Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 3, pp. 329-337

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

  2. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: A retrospective multicenter case-control study

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 89-95